Chimerix, Inc.
NASDAQ:CMRX
Overview | Financials
Company Name | Chimerix, Inc. |
Symbol | CMRX |
Currency | USD |
Price | 3.47 |
Market Cap | 312,078,267 |
Dividend Yield | 0% |
52-week-range | 0.75 - 3.8 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael T. Andriole M.B.A. |
Website | https://www.chimerix.com |
An error occurred while fetching data.
About Chimerix, Inc.
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD